Therapeutic area intelligence for HER2 Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Roche →

Assets

PERJETA →

Recent signals(1)

RegulatoryJuly 5, 2026

FDA Accepts Supplemental Application for PERJETA by Genentech

The FDA has accepted a supplemental application for PERJETA (pertuzumab) from Genentech.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.